Acura Pharmaceuticals Inc (ACUR)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Acura Pharmaceuticals Inc (ACUR) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011465
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tampering associated with opioid abuse. Its Impede technology helps minimize the extraction and conversion of pseudoephedrine into methamphetamine. Limitx reduces the level of opioid release when several tablets are swallowed. Aversion irritates the nasal passages upon snorting the product Its product portfolio includes Oxaydo, an opioid analgesic; Nexafed and Nexafed Sinus Pressure plus that contain pseudoephedrine. The company markets its products in the US and Canada. Acura is headquartered in Palatine, Illinois, the US.

Acura Pharmaceuticals Inc (ACUR) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Acura Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Acura Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Acura Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Acura Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Acura Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Acura Pharmaceuticals Inc, Medical Equipment, Deal Details 10
Equity Offering 10
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 10
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For US$3.4 Million 11
Acquisition 12
Acura Pharma Plans to Sell Itself 12
Acura Pharmaceuticals Inc – Key Competitors 13
Acura Pharmaceuticals Inc – Key Employees 14
Acura Pharmaceuticals Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Recent Developments 16
Financial Announcements 16
Nov 13, 2017: Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results 16
Aug 14, 2017: Acura Pharmaceuticals Announces Second Quarter 2017 Financial Results 17
May 12, 2017: Acura Pharmaceuticals Announces First Quarter 2017 Financial Results 18
Mar 31, 2017: Acura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results 19
Nov 14, 2016: Acura Pharmaceuticals Announces Third Quarter 2016 Financial Results 20
Aug 08, 2016: Acura Pharmaceuticals Announces Second Quarter 2016 Financial Results 21
May 02, 2016: Acura Pharmaceuticals Announces First Quarter 2016 Financial Results 22
Feb 29, 2016: Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Acura Pharmaceuticals Inc, Medical Equipment, Key Facts, 2016 2
Acura Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Acura Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Acura Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Acura Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Acura Pharmaceuticals Inc, Deals By Market, 2011 to YTD 2017 8
Acura Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 10
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For US$3.4 Million 11
Acura Pharma Plans to Sell Itself 12
Acura Pharmaceuticals Inc, Key Competitors 13
Acura Pharmaceuticals Inc, Key Employees 14
Acura Pharmaceuticals Inc, Other Locations 15
Acura Pharmaceuticals Inc, Subsidiaries 15

★海外企業調査レポート[Acura Pharmaceuticals Inc (ACUR)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vietnam Joint Stock Commercial Bank for Industry and Trade:企業の戦略・SWOT・財務情報
    Vietnam Joint Stock Commercial Bank for Industry and Trade - Strategy, SWOT and Corporate Finance Report Summary Vietnam Joint Stock Commercial Bank for Industry and Trade - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the …
  • Clinova Ltd:企業の戦略的SWOT分析
    Clinova Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • PT Pembangkitan Jawa-Bali-エネルギー分野:企業M&A・提携分析
    Summary PT Pembangkitan Jawa-Bali (PJB), a subsidiary of PT PLN (Persero), generates and supplies electricity. It is responsible to meet the electricity requirements of the Java-Madura-Bali (JAMALI) electric system. The company generates electricity from energy sources such as oil, natural gas, coal …
  • Nanolek-製薬・医療分野:企業M&A・提携分析
    Summary Nanolek specializes in the production of import-substituting and novel pharmaceuticals. The company’s product portfolio includes vaccines; drugs for treatment of leukemias, brain cancer, breast cancer, stomach and ovarian cancer, colorectal cancer, HIV infection and other diseases. Nanolek a …
  • Azul SA (AZUL):企業の財務・戦略的SWOT分析
    Azul SA (AZUL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Sernova Corp (SVA):医療機器:M&Aディール及び事業提携情報
    Summary Sernova Corp (Sernova) is a clinical stage regenerative medicines company which develops and commercializes medical device and combination products for the treatment of chronic diseases. The company develops Cell Pouch System, an implantable medical device, which offers a natural organ-like …
  • Gulf Resources Inc (GURE):企業の財務・戦略的SWOT分析
    Gulf Resources Inc (GURE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Ascendant Group Limited (AGL.BH):企業の戦略的SWOT分析
    Ascendant Group Limited (AGL.BH) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • MVV Energie AG:企業の戦略・SWOT・財務情報
    MVV Energie AG - Strategy, SWOT and Corporate Finance Report Summary MVV Energie AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • BlackBerry Ltd:戦略・SWOT・企業財務分析
    BlackBerry Ltd - Strategy, SWOT and Corporate Finance Report Summary BlackBerry Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • EQT Corp (EQT):企業の財務・戦略的SWOT分析
    EQT Corp (EQT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Geron Corp (GERN)-製薬・医療分野:企業M&A・提携分析
    Summary Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. …
  • Gold Fields Ltd:戦略・SWOT・企業財務分析
    Gold Fields Ltd - Strategy, SWOT and Corporate Finance Report Summary Gold Fields Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Kaiser Permanente:企業の戦略・SWOT・財務分析
    Kaiser Permanente - Strategy, SWOT and Corporate Finance Report Summary Kaiser Permanente - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Las Vegas Sands Corp:企業の戦略・SWOT・財務情報
    Las Vegas Sands Corp - Strategy, SWOT and Corporate Finance Report Summary Las Vegas Sands Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • University of Maryland Medical Center Corp:企業の戦略的SWOT分析
    University of Maryland Medical Center Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Hammerson plc:企業のM&A・事業提携・投資動向
    Hammerson plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hammerson plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Orange SA:戦略・SWOT・企業財務分析
    Orange SA - Strategy, SWOT and Corporate Finance Report Summary Orange SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Central National Gottesman Inc:企業の戦略・SWOT・財務分析
    Central National Gottesman Inc - Strategy, SWOT and Corporate Finance Report Summary Central National Gottesman Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Nestle Australia Ltd:企業の戦略・SWOT・財務情報
    Nestle Australia Ltd - Strategy, SWOT and Corporate Finance Report Summary Nestle Australia Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆